Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 11/20 | 0.68 |
| ▸ | IGF1R | P08069 | 11/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.68 |
| ▸ | EGFR | P00533 | 10/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | STK10 | O94804 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CD74 | P04233 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | FES | P07332 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | YES1 | P07947 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23260568 | 0.91 | EGFR (0.64) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL23153995 | 0.90 | INSR (0.70) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL23259839 | 0.90 | EGFR (0.74) | INSRIGF1RALKEGFR | |
| SCHEMBL24817939 | 0.89 | ALK (0.84) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL23259938 | 0.89 | EGFR (0.56) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL24940738 | 0.89 | ALK (0.76) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL31498848 | 0.89 | ALK (0.76) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL23154088 | 0.88 | INSR (0.72) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL23154153 | 0.88 | INSR (0.69) | INSRIGF1RALKEGFRCHEK1 | |
| SCHEMBL24755232 | 0.88 | INSR (0.67) | INSRIGF1RALKEGFRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | claimed |
| CN-114430741-A | EGFR inhibitor, composition and preparation method thereof | 贝达药业股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-114430741-A | EGFR inhibitor, composition and preparation method thereof | 贝达药业股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2021073498-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | 贝达药业股份有限公司 | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | EGFR, ERBB2, ERBB3 | INSR 162/4885IGF1R 26/4885ALK 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.